Literature DB >> 22105069

Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity.

Suhman Chung1, Jennifer T Miller, Barry C Johnson, Stephen H Hughes, Stuart F J Le Grice.   

Abstract

The vinylogous urea, NSC727447, was proposed to allosterically inhibit ribonuclease H (RNase H) activity of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) by interacting with the thumb subdomain of its non-catalytic p51 subunit. Proximity of the p51 thumb to the p66 RNase H domain implied that inhibitor binding altered active site geometry, whereas protein footprinting suggested a contribution from α-helix I residues Cys-280 and Lys-281. To more thoroughly characterize the vinylogous urea binding site, horizontal alanine scanning mutagenesis between p51 residues Lys-275 and Thr-286 (comprising α-helix I and portions of the neighboring αH/αI and αI/αJ connecting loops) was combined with a limited vertical scan of Cys-280. A contribution from Cys-280 was strengthened by our observation that all substitutions at this position rendered selectively mutated, reconstituted p66/p51 heterodimers ∼45-fold less sensitive to inhibition. An ∼19-fold reduced IC(50) for p51 mutant T286A coupled with a 2-8-fold increased IC(50) when intervening residues were substituted supports our original proposal of p51 α-helix I as the vinylogous urea binding site. In contrast to these allosteric inhibitors, mutant enzymes retained equivalent sensitivity to the natural product α-hydroxytropolone inhibitor manicol, which x-ray crystallography has demonstrated functions by chelating divalent metal at the p66 RNase H active site. Finally, reduced DNA strand-transfer activity together with increased vinylogous urea sensitivity of p66/p51 heterodimers containing short p51 C-terminal deletions suggests an additional role for the p51 C terminus in nucleic acid binding that is compromised by inhibitor binding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105069      PMCID: PMC3281700          DOI: 10.1074/jbc.M111.314781

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid.

Authors:  Cathryn A Shaw-Reid; Vandna Munshi; Pia Graham; Abigail Wolfe; Marc Witmer; Renee Danzeisen; David B Olsen; Steven S Carroll; Mark Embrey; John S Wai; Michael D Miller; James L Cole; Daria J Hazuda
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

2.  Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.

Authors:  Suhman Chung; Daniel M Himmel; Jian-Kang Jiang; Krzysztof Wojtak; Joseph D Bauman; Jason W Rausch; Jennifer A Wilson; John A Beutler; Craig J Thomas; Eddy Arnold; Stuart F J Le Grice
Journal:  J Med Chem       Date:  2011-06-02       Impact factor: 7.446

3.  Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.

Authors:  N Sluis-Cremer; G I Dmitrienko; J Balzarini; M J Camarasa; M A Parniak
Journal:  Biochemistry       Date:  2000-02-15       Impact factor: 3.162

4.  Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.

Authors:  S F Le Grice; F Grüninger-Leitch
Journal:  Eur J Biochem       Date:  1990-01-26

5.  Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Authors:  S G Sarafianos; K Das; C Tantillo; A D Clark; J Ding; J M Whitcomb; P L Boyer; S H Hughes; E Arnold
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

6.  Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity.

Authors:  Jason W Rausch; Daniela Lener; Jennifer T Miller; John G Julias; Stephen H Hughes; Stuart F J Le Grice
Journal:  Biochemistry       Date:  2002-04-16       Impact factor: 3.162

7.  Mutagenesis of cysteine 280 of the reverse transcriptase of human immunodeficiency virus type-1: the effects on the ribonuclease H activity.

Authors:  Ziv Sevilya; Shoshana Loya; Amit Duvshani; Noam Adir; Amnon Hizi
Journal:  J Mol Biol       Date:  2003-03-14       Impact factor: 5.469

8.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

9.  Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors.

Authors:  Klaus Klumpp; Julie Qi Hang; Surendran Rajendran; Yanli Yang; Andre Derosier; Philippe Wong Kai In; Hilary Overton; Kevin E B Parkes; Nick Cammack; Joseph A Martin
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

10.  Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.

Authors:  S F Le Grice; T Naas; B Wohlgensinger; O Schatz
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  17 in total

1.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise.

Authors:  Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

3.  Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

4.  Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitors.

Authors:  Angela Corona; Anna Schneider; Kristian Schweimer; Paul Rösch; Birgitta M Wöhrl; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives.

Authors:  Angela Corona; Francesco Saverio Di Leva; Sylvain Thierry; Luca Pescatori; Giuliana Cuzzucoli Crucitti; Frederic Subra; Olivier Delelis; Francesca Esposito; Giuseppe Rigogliuso; Roberta Costi; Sandro Cosconati; Ettore Novellino; Roberto Di Santo; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Examining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids.

Authors:  Suhman Chung; Jennifer T Miller; Mikalai Lapkouski; Lan Tian; Wei Yang; Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2013-04-17       Impact factor: 5.157

Review 7.  Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase.

Authors:  Angela Corona; Takashi Masaoka; Graziella Tocco; Enzo Tramontano; Stuart F J Le Grice
Journal:  Future Med Chem       Date:  2013-12       Impact factor: 3.808

8.  Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.

Authors:  Takashi Masaoka; Suhman Chung; Pierluigi Caboni; Jason W Rausch; Jennifer A Wilson; Humeyra Taskent-Sezgin; John A Beutler; Graziella Tocco; Stuart F J Le Grice
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

9.  Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies.

Authors:  Vasanthanathan Poongavanam; Angela Corona; Casper Steinmann; Luigi Scipione; Nicole Grandi; Fabiana Pandolfi; Roberto Di Santo; Roberta Costi; Francesca Esposito; Enzo Tramontano; Jacob Kongsted
Journal:  Medchemcomm       Date:  2018-02-01       Impact factor: 3.597

10.  Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity.

Authors:  Tatiana Ilina; Krystal Labarge; Stefan G Sarafianos; Rieko Ishima; Michael A Parniak
Journal:  Biology (Basel)       Date:  2012-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.